Engchem Life Sciences "Oral Mucositis Phase 2 Clinical Trial Topline Results to be Announced in Q3"

[Asia Economy Reporter Jihee Kim] Engchem Life Sciences announced on the 15th that it hosted a conference on immuno-oncology at Bio Korea 2021 and introduced the development plan for its new drug candidate 'EC-18'.

At Bio Korea, held over three days from the 9th to the 11th, Engchem Life Sciences hosted the conference titled ‘Latest Research on Immuno-oncology Therapy to Improve Cancer Patient Survival Rates.’ Dr. Gapjoo Park served as the chair and invited domestic and international experts in immuno-oncology clinical trials as speakers.

Professor Jeff Crawford of Duke University School of Medicine, a member of Engchem Life Sciences' Scientific Advisory Board (SAB) and a world-renowned authority in clinical immuno-oncology, also attended. He presented research findings showing that EC-18, Engchem Life Sciences' new drug candidate, removes extracellular adenosine (eADO), the fundamental cause of the immunosuppressive tumor microenvironment (TME), thereby producing a synergistic effect as a combination therapy with immune checkpoint inhibitors.

During the real-time online business forum, the development plan for EC-18 was introduced. Engchem Life Sciences stated that it expects to announce the topline results of the global Phase 2 clinical trial for the indication of oral mucositis in the third quarter.

Dr. Gapjoo Park of Engchem Life Sciences said, "Engchem Life Sciences will achieve strategic technology transfers and partnerships with global pharmaceutical companies based on the Phase 2 clinical trial results for key indications."